{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:17:02Z","timestamp":1792556222682,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Improved systemic therapy has made long term (\u2265\u20095 years) overall survival (LTS) after resection of pancreatic ductal adenocarcinoma (PDAC) increasingly common. However, a systematic review on predictors of LTS following resection of PDAC is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The PubMed, Embase, Scopus, and Cochrane CENTRAL databases were systematically searched from inception until March 2023. Studies reporting actual survival data (based on follow-up and not survival analysis estimates) on factors associated with LTS were included. Meta-analyses were conducted by using a random effects model, and study quality was gauged by using the Newcastle-Ottawa Scale (NOS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-five studies with 27,091 patients\u00a0(LTS: 2,132, non-LTS: 24,959) who underwent surgical resection for PDAC were meta-analyzed. The median proportion of LTS patients was 18.32% (IQR 12.97\u201321.18%) based on 20 studies. Predictors for LTS included sex, body mass index (BMI), preoperative levels of CA19-9, CEA, and albumin, neutrophil-lymphocyte ratio, tumor grade, AJCC stage, lymphovascular and perineural invasion, pathologic T-stage, nodal disease, metastatic disease, margin status, adjuvant therapy, vascular resection, operative time, operative blood loss, and perioperative blood transfusion. Most articles received a \u201cgood\u201d NOS assessment, indicating an acceptable risk of bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our meta-analysis pools all true follow up data in the literature to quantify associations between prognostic factors and LTS after resection of PDAC. While there appears to be evidence of a complex interplay between risk, tumor biology, patient characteristics, and management related factors, no single parameter can predict LTS after the resection of PDAC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-024-15281-1","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T15:01:49Z","timestamp":1715007709000},"page":"4673-4687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Predictors for Long-Term Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis"],"prefix":"10.1245","volume":"31","author":[{"given":"Ammar A.","family":"Javed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Mahmud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad Saulat","family":"Fatimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssar","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahip","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Wolfgang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G.","family":"Besselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the PANC-PALS Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"15281_CR1","unstructured":"Pancreatic Cancer\u2014Cancer Stat Facts. Accessed 11 Oct 2022. https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html"},{"key":"15281_CR2","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.3389\/FONC.2021.688377\/BIBTEX","volume":"11","author":"DR Principe","year":"2021","unstructured":"Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy. Front Oncol. 2021;11:2773. https:\/\/doi.org\/10.3389\/FONC.2021.688377\/BIBTEX.","journal-title":"Front Oncol."},{"key":"15281_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-019-6251-7","author":"Z Wang","year":"2019","unstructured":"Wang Z, Li Y, Zhan S, et al. SMAD4 Y353C promotes the progression of PDAC. BMC Cancer. 2019. https:\/\/doi.org\/10.1186\/S12885-019-6251-7.","journal-title":"BMC Cancer."},{"issue":"5","key":"15281_CR4","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","volume":"267","author":"VP Groot","year":"2018","unstructured":"Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267(5):936\u201345. https:\/\/doi.org\/10.1097\/SLA.0000000000002234.","journal-title":"Ann Surg."},{"issue":"27","key":"15281_CR5","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.20.01364","volume":"38","author":"DPS Sohal","year":"2020","unstructured":"Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020;38(27):3217\u201330. https:\/\/doi.org\/10.1200\/JCO.20.01364.","journal-title":"J Clin Oncol."},{"issue":"2","key":"15281_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41575-020-00410-4","volume":"18","author":"T Jain","year":"2021","unstructured":"Jain T, Dudeja V. The war against pancreatic cancer in 2020\u2014advances on all fronts. Nat Rev Gastroenterol Hepatol. 2021;18(2):99\u2013100. https:\/\/doi.org\/10.1038\/s41575-020-00410-4.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"1","key":"15281_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-73525-y","volume":"10","author":"A Bengtsson","year":"2020","unstructured":"Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep. 2020;10(1):1\u20139. https:\/\/doi.org\/10.1038\/s41598-020-73525-y.","journal-title":"Sci Rep."},{"issue":"7706","key":"15281_CR8","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1136\/BMJ.B375","volume":"338","author":"KGM Moons","year":"2009","unstructured":"Moons KGM, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why, and how? BMJ. 2009;338(7706):1317\u201320. https:\/\/doi.org\/10.1136\/BMJ.B375.","journal-title":"BMJ."},{"issue":"35","key":"15281_CR9","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.3748\/WJG.V27.I35.5851","volume":"27","author":"V Tonini","year":"2021","unstructured":"Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. World J Gastroenterol. 2021;27(35):5851\u201389. https:\/\/doi.org\/10.3748\/WJG.V27.I35.5851.","journal-title":"World J Gastroenterol."},{"issue":"1","key":"15281_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol."},{"issue":"1","key":"15281_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40779-021-00331-6","volume":"8","author":"JJ Wei","year":"2021","unstructured":"Wei JJ, Lin EX, Shi JD, et al. Meta-analysis with zero-event studies: a comparative study with application to COVID-19 data. Mil Med Res. 2021;8(1):41. https:\/\/doi.org\/10.1186\/s40779-021-00331-6.","journal-title":"Mil Med Res."},{"issue":"7","key":"15281_CR12","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/sim.6383","volume":"34","author":"O Kuss","year":"2015","unstructured":"Kuss O. Statistical methods for meta-analyses including information from studies without any events\u2014add nothing to nothing and succeed nevertheless. Stat Med. 2015;34(7):1097\u2013116. https:\/\/doi.org\/10.1002\/sim.6383.","journal-title":"Stat Med."},{"key":"15281_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jclinepi.2020.03.020","volume":"123","author":"C Xu","year":"2020","unstructured":"Xu C, Li L, Lin L, et al. Exclusion of studies with no events in both arms in meta-analysis impacted the conclusions. J Clin Epidemiol. 2020;123:91\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2020.03.020.","journal-title":"J Clin Epidemiol."},{"issue":"7650","key":"15281_CR14","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ."},{"issue":"13","key":"15281_CR15","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.1245\/S10434-021-10401-7\/TABLES\/5","volume":"28","author":"G Belfiori","year":"2021","unstructured":"Belfiori G, Crippa S, Francesca A, et al. Long-term survivors after upfront resection for pancreatic ductal adenocarcinoma: an actual 5-year analysis of disease-specific and post-recurrence survival. Ann Surg Oncol. 2021;28(13):8249\u201360. https:\/\/doi.org\/10.1245\/S10434-021-10401-7\/TABLES\/5.","journal-title":"Ann Surg Oncol."},{"key":"15281_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/(SICI)1096-9098(200004)73:4","volume":"73","author":"G Benassai","year":"2000","unstructured":"Benassai G, Mastrorilli M, Quarto G, et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol. 2000;73:212\u20138. https:\/\/doi.org\/10.1002\/(SICI)1096-9098(200004)73:4.","journal-title":"J Surg Oncol."},{"key":"15281_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/00000658-199603000-00007","volume":"223","author":"KCMD Conlon","year":"1996","unstructured":"Conlon KCMD, Klimstra DSMD, Brennan MFMD, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma: Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996;223:273\u20139.","journal-title":"Ann Surg."},{"issue":"8","key":"15281_CR18","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1158\/1078-0432.CCR-14-2600","volume":"21","author":"M Dal Molin","year":"2015","unstructured":"Dal Molin M, Zhang M, De Wilde RF, et al. Very long-term survival following resection for pancreatic cancer is not explained by commonly mutated genes: results of whole-exome sequencing analysis. Clin Cancer Res. 2015;21(8):1944\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2600.","journal-title":"Clin Cancer Res."},{"issue":"5","key":"15281_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0002-9610(96)00237-1","volume":"172","author":"R Delcore","year":"1996","unstructured":"Delcore R, Rodriguez FJ, Forster J, Hermreck AS, Thomas JH. Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. Am J Surg. 1996;172(5):463\u20139. https:\/\/doi.org\/10.1016\/S0002-9610(96)00237-1.","journal-title":"Am J Surg."},{"issue":"4","key":"15281_CR20","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/S11605-013-2408-X\/TABLES\/4","volume":"18","author":"N Dusch","year":"2014","unstructured":"Dusch N, Weiss C, Str\u00f6bel P, Kienle P, Post S, Niedergethmann M. Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg. 2014;18(4):674\u201381. https:\/\/doi.org\/10.1007\/S11605-013-2408-X\/TABLES\/4.","journal-title":"J Gastrointest Surg."},{"issue":"3","key":"15281_CR21","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/J.SURG.2012.05.020","volume":"152","author":"CR Ferrone","year":"2012","unstructured":"Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, et al. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012;152(3):S43\u20139. https:\/\/doi.org\/10.1016\/J.SURG.2012.05.020.","journal-title":"Surgery."},{"issue":"8","key":"15281_CR22","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1053\/HUPA.2001.26473","volume":"32","author":"N Fukushima","year":"2001","unstructured":"Fukushima N, Sakamoto M, Mukai K, et al. Intraductal papillary components in invasive ductal carcinoma of the pancreas are associated with long-term survival of patients. Hum Pathol. 2001;32(8):834\u201341. https:\/\/doi.org\/10.1053\/HUPA.2001.26473.","journal-title":"Hum Pathol."},{"key":"15281_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/1010428320936410","author":"M Holm","year":"2020","unstructured":"Holm M, Saraswat M, Joenv\u00e4\u00e4r\u00e4 S, Sepp\u00e4nen H, Renkonen R, Haglund C. Label-free proteomics reveals serum proteins whose levels differ between pancreatic ductal adenocarcinoma patients with short or long survival. Tumor Biol. 2020. https:\/\/doi.org\/10.1177\/1010428320936410.","journal-title":"Tumor Biol."},{"key":"15281_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/J.IJSU.2017.02.007","volume":"40","author":"SH Han","year":"2017","unstructured":"Han SH, Heo JS, Choi SH, et al. Actual long-term outcome of T1 and T2 pancreatic ductal adenocarcinoma after surgical resection. Int J Surg. 2017;40:68\u201372. https:\/\/doi.org\/10.1016\/J.IJSU.2017.02.007.","journal-title":"Int J Surg."},{"issue":"8","key":"15281_CR25","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1097\/MPA.0000000000001133","volume":"47","author":"A Kardosh","year":"2018","unstructured":"Kardosh A, Lichtensztajn DY, Gubens MA, Kunz PL, Fisher GA, Clarke CA. Long-term survivors of pancreatic cancer: a California population-based study. Pancreas. 2018;47(8):958\u201366. https:\/\/doi.org\/10.1097\/MPA.0000000000001133.","journal-title":"Pancreas."},{"issue":"4","key":"15281_CR26","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1245\/S10434-008-0295-2\/TABLES\/5","volume":"16","author":"MHG Katz","year":"2009","unstructured":"Katz MHG, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16(4):836\u201347. https:\/\/doi.org\/10.1245\/S10434-008-0295-2\/TABLES\/5.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"15281_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7819-12-360\/FIGURES\/2","volume":"12","author":"K Kimura","year":"2014","unstructured":"Kimura K, Amano R, Nakata B, et al. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma. World J Surg Oncol. 2014;12(1):1\u20138. https:\/\/doi.org\/10.1186\/1477-7819-12-360\/FIGURES\/2.","journal-title":"World J Surg Oncol."},{"issue":"3","key":"15281_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/J.HBPD.2020.12.006","volume":"20","author":"AM Luu","year":"2021","unstructured":"Luu AM, Braumann C, Belyaev O, et al. Long-term survival after pancreaticoduodenectomy in patients with ductal adenocarcinoma of the pancreatic head. Hepatobil Pancreatic Dis Int. 2021;20(3):271\u20138. https:\/\/doi.org\/10.1016\/J.HBPD.2020.12.006.","journal-title":"Hepatobil Pancreatic Dis Int."},{"issue":"6","key":"15281_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/S00423-018-1709-7\/FIGURES\/4","volume":"403","author":"K Nakagawa","year":"2018","unstructured":"Nakagawa K, Akahori T, Nishiwada S, et al. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Langenbecks Arch Surg. 2018;403(6):693\u2013700. https:\/\/doi.org\/10.1007\/S00423-018-1709-7\/FIGURES\/4.","journal-title":"Langenbecks Arch Surg."},{"issue":"3","key":"15281_CR30","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1245\/S10434-019-08047-7","volume":"27","author":"N Nakagawa","year":"2020","unstructured":"Nakagawa N, Yamada S, Sonohara F, et al. Clinical implications of naples prognostic score in patients with resected pancreatic cancer. Ann Surg Oncol. 2020;27(3):887\u201395. https:\/\/doi.org\/10.1245\/S10434-019-08047-7.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"15281_CR31","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1002\/CAM4.1178","volume":"6","author":"Y Nakano","year":"2017","unstructured":"Nakano Y, Kitago M, Shinoda M, et al. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study. Cancer Med. 2017;6(10):2278\u201386. https:\/\/doi.org\/10.1002\/CAM4.1178.","journal-title":"Cancer Med."},{"issue":"8","key":"15281_CR32","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/JAMASURG.2015.0668","volume":"150","author":"A Paniccia","year":"2015","unstructured":"Paniccia A, Hosokawa P, Henderson W, et al. Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma. JAMA Surg. 2015;150(8):701\u201310. https:\/\/doi.org\/10.1001\/JAMASURG.2015.0668.","journal-title":"JAMA Surg."},{"issue":"6","key":"15281_CR33","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1245\/S10434-016-5716-Z\/TABLES\/4","volume":"24","author":"VJ Picozzi","year":"2017","unstructured":"Picozzi VJ, Oh SY, Edwards A, et al. Five-year actual overall survival in resected pancreatic cancer: a contemporary single-institution experience from a multidisciplinary perspective. Ann Surg Oncol. 2017;24(6):1722\u201330. https:\/\/doi.org\/10.1245\/S10434-016-5716-Z\/TABLES\/4.","journal-title":"Ann Surg Oncol."},{"key":"15281_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3389\/FIMMU.2021.643529\/BIBTEX","volume":"12","author":"H Sadozai","year":"2021","unstructured":"Sadozai H, Acharjee A, Eppenberger-Castori S, et al. Distinct stromal and immune features collectively contribute to long-term survival in pancreatic cancer. Front Immunol. 2021;12:307. https:\/\/doi.org\/10.3389\/FIMMU.2021.643529\/BIBTEX.","journal-title":"Front Immunol."},{"issue":"3","key":"15281_CR35","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/SLA.0B013E3181613142","volume":"247","author":"T Schnelldorfer","year":"2008","unstructured":"Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma is cure possible? Ann Surg. 2008;247(3):456\u201362. https:\/\/doi.org\/10.1097\/SLA.0B013E3181613142.","journal-title":"Ann Surg."},{"issue":"8","key":"15281_CR36","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1007\/S00268-010-0570-9\/TABLES\/4","volume":"34","author":"K Shimada","year":"2010","unstructured":"Shimada K, Sakamoto Y, Nara S, Esaki M, Kosuge T, Hiraoka N. Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg. 2010;34(8):1908\u201315. https:\/\/doi.org\/10.1007\/S00268-010-0570-9\/TABLES\/4.","journal-title":"World J Surg."},{"issue":"4","key":"15281_CR37","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/MPA.0000000000000063","volume":"43","author":"SH Shin","year":"2014","unstructured":"Shin SH, Kim SC, Hong SM, et al. Can statistically determined prognostic factors predict the long-term survival of patients with pancreatic ductal adenocarcinoma following surgical resection? Clinicopathological analysis of 82 long-term survivors. Pancreas. 2014;43(4):571\u20137. https:\/\/doi.org\/10.1097\/MPA.0000000000000063.","journal-title":"Pancreas."},{"issue":"6","key":"15281_CR38","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/JSO.23409","volume":"108","author":"M Sinn","year":"2013","unstructured":"Sinn M, Striefler JK, Sinn BV, et al. Does long-term survival in patients with pancreatic cancer really exist?\u2014Results from the CONKO-001 study. J Surg Oncol. 2013;108(6):398\u2013402. https:\/\/doi.org\/10.1002\/JSO.23409.","journal-title":"J Surg Oncol."},{"issue":"1","key":"15281_CR39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3748\/wjg.v21.i1.262","volume":"21","author":"T Yamamoto","year":"2015","unstructured":"Yamamoto T, Yagi S, Kinoshita H, et al. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis. World J Gastroenterol. 2015;21(1):262\u20138. https:\/\/doi.org\/10.3748\/wjg.v21.i1.262.","journal-title":"World J Gastroenterol."},{"issue":"6","key":"15281_CR40","doi-asserted-by":"publisher","first-page":"394","DOI":"10.4174\/JKSS.2011.81.6.394","volume":"81","author":"KW Yoon","year":"2011","unstructured":"Yoon KW, Heo JS, Choi DW, Choi SH. Factors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma. J Korean Surg Soc. 2011;81(6):394\u2013401. https:\/\/doi.org\/10.4174\/JKSS.2011.81.6.394.","journal-title":"J Korean Surg Soc."},{"key":"15281_CR41","doi-asserted-by":"publisher","first-page":"102724","DOI":"10.1016\/J.AMSU.2021.102724","volume":"69","author":"SK Burgdorf","year":"2021","unstructured":"Burgdorf SK, Storkholm JH, Chen IM, Hansen CP. Postoperative and long-term survival in relation to life-expectancy after pancreatic surgery in elderly patients (cohort study). Ann Med Surg. 2021;69:102724. https:\/\/doi.org\/10.1016\/J.AMSU.2021.102724.","journal-title":"Ann Med Surg."},{"issue":"7","key":"15281_CR42","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1245\/S10434-012-2809-1\/FIGURES\/5","volume":"20","author":"W Hartwig","year":"2013","unstructured":"Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20(7):2188\u201396. https:\/\/doi.org\/10.1245\/S10434-012-2809-1\/FIGURES\/5.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"15281_CR43","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/J.HPB.2021.10.011","volume":"24","author":"H Huhta","year":"2022","unstructured":"Huhta H, Nortunen M, Meril\u00e4inen S, Helminen O, Kauppila JH. Hospital volume and outcomes of pancreatic cancer: a Finnish population-based nationwide study. HPB. 2022;24(6):841\u20137. https:\/\/doi.org\/10.1016\/J.HPB.2021.10.011.","journal-title":"HPB."},{"issue":"5","key":"15281_CR44","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/J.PAN.2017.08.013","volume":"17","author":"JS Kang","year":"2017","unstructured":"Kang JS, Jang JY, Kwon W, Han Y, Kim SW. Clinicopathologic and survival differences in younger patients with pancreatic ductal adenocarcinoma\u2014a propensity score-matched comparative analysis. Pancreatology. 2017;17(5):827\u201332. https:\/\/doi.org\/10.1016\/J.PAN.2017.08.013.","journal-title":"Pancreatology."},{"issue":"4","key":"15281_CR45","first-page":"2011","volume":"36","author":"Y Shirai","year":"2016","unstructured":"Shirai Y, Shiba H, Horiuchi T, et al. Assessment of surgical outcome after pancreatic resection in extremely elderly patients. Anticancer Res. 2016;36(4):2011\u20137.","journal-title":"Anticancer Res."},{"issue":"11","key":"15281_CR46","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1245\/S10434-017-5994-0\/TABLES\/4","volume":"24","author":"T Sugiura","year":"2017","unstructured":"Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Uesaka K. Impact of patient age on the postoperative survival in pancreatic head cancer. Ann Surg Oncol. 2017;24(11):3220\u20138. https:\/\/doi.org\/10.1245\/S10434-017-5994-0\/TABLES\/4.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"15281_CR47","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/J.JCMGH.2020.04.016","volume":"10","author":"CA Natale","year":"2020","unstructured":"Natale CA, Li J, Pitarresi JR, et al. Pharmacologic activation of the G protein-coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma. Cell Mol Gastroenterol Hepatol. 2020;10(4):868-80.e1. https:\/\/doi.org\/10.1016\/J.JCMGH.2020.04.016.","journal-title":"Cell Mol Gastroenterol Hepatol."},{"key":"15281_CR48","unstructured":"Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer | CJS. Accessed 15 March 2023. https:\/\/www.canjsurg.ca\/content\/49\/4\/241.long"},{"issue":"1","key":"15281_CR49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/J.JAMCOLLSURG.2016.02.009","volume":"223","author":"JR Bergquist","year":"2016","unstructured":"Bergquist JR, Puig CA, Shubert CR, et al. Carbohydrate antigen 19\u20139 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: A national cancer database study. J Am Coll Surg. 2016;223(1):52\u201365. https:\/\/doi.org\/10.1016\/J.JAMCOLLSURG.2016.02.009.","journal-title":"J Am Coll Surg."},{"issue":"6","key":"15281_CR50","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/S00534-006-1184-3","volume":"14","author":"S Fujioka","year":"2007","unstructured":"Fujioka S, Misawa T, Okamoto T, et al. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19\u20139 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg. 2007;14(6):539\u201344. https:\/\/doi.org\/10.1007\/S00534-006-1184-3.","journal-title":"J Hepatobiliary Pancreat Surg."},{"issue":"9","key":"15281_CR51","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/J.GASSUR.2005.06.008","volume":"9","author":"A Karachristos","year":"2005","unstructured":"Karachristos A, Scarmeas N, Hoffman JP. CA 19\u20139 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg. 2005;9(9):1286\u201392. https:\/\/doi.org\/10.1016\/J.GASSUR.2005.06.008.","journal-title":"J Gastrointest Surg."},{"issue":"12","key":"15281_CR52","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1245\/S10434-008-0134-5","volume":"15","author":"SK Maithel","year":"2008","unstructured":"Maithel SK, Maloney S, Winston C, et al. Preoperative CA 19\u20139 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2008;15(12):3512\u201320. https:\/\/doi.org\/10.1245\/S10434-008-0134-5.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"15281_CR53","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/SJ.BJC.6602760","volume":"93","author":"NR Maisey","year":"2005","unstructured":"Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93(7):740\u20133. https:\/\/doi.org\/10.1038\/SJ.BJC.6602760.","journal-title":"Br J Cancer."},{"key":"15281_CR54","unstructured":"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer - UpToDate. Accessed 15 March 2023. https:\/\/www.uptodate.com\/contents\/clinical-manifestations-diagnosis-and-staging-of-exocrine-pancreatic-cancer?search=CA-199&source=search_result&selectedTitle=1~63&usage_type=default&display_rank=1#H1620046"},{"issue":"4","key":"15281_CR55","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1245\/S10434-010-1397-1","volume":"18","author":"SRZ Abdel-Misih","year":"2011","unstructured":"Abdel-Misih SRZ, Hatzaras I, Schmidt C, et al. Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease. Ann Surg Oncol. 2011;18(4):1116\u201321. https:\/\/doi.org\/10.1245\/S10434-010-1397-1.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"15281_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, Korc M, Apte M, et al. 2016 Pancreatic cancer. Nat Rev Dis Primers. 2016;2(1):1\u201322. https:\/\/doi.org\/10.1038\/nrdp.2016.22.","journal-title":"Nat Rev Dis Primers."},{"key":"15281_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.643529","author":"H Sadozai","year":"2021","unstructured":"Sadozai H, Acharjee A, Eppenberger-Castori S, et al. Distinct stromal and immune features collectively contribute to long-term survival in pancreatic cancer. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.643529.","journal-title":"Front Immunol."},{"issue":"5","key":"15281_CR58","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/J.JCMGH.2021.06.023","volume":"12","author":"FR Delvecchio","year":"2021","unstructured":"Delvecchio FR, Fincham REA, Spear S, et al. Pancreatic cancer chemotherapy is potentiated by induction of tertiary lymphoid structures in mice. Cell Mol Gastroenterol Hepatol. 2021;12(5):1543\u201365. https:\/\/doi.org\/10.1016\/J.JCMGH.2021.06.023.","journal-title":"Cell Mol Gastroenterol Hepatol."},{"issue":"4","key":"15281_CR59","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1535-7163.MCT-08-1096","volume":"8","author":"J Guillermet-Guibert","year":"2009","unstructured":"Guillermet-Guibert J, Davenne L, Pchejetski D, et al. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther. 2009;8(4):809\u201320. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-1096.","journal-title":"Mol Cancer Ther."},{"issue":"1","key":"15281_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, Korc M, Apte M, et al. 2016 Pancreatic cancer. Nat Rev Disease Primers. 2016;2(1):1\u201322. https:\/\/doi.org\/10.1038\/nrdp.2016.22.","journal-title":"Nat Rev Disease Primers."},{"issue":"5","key":"15281_CR61","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41571-022-00612-6","volume":"19","author":"C Springfeld","year":"2022","unstructured":"Springfeld C, Neoptolemos JP. The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain. Nat Rev Clin Oncol. 2022;19(5):285\u20136. https:\/\/doi.org\/10.1038\/s41571-022-00612-6.","journal-title":"Nat Rev Clin Oncol."},{"key":"15281_CR62","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3389\/FONC.2020.00245\/BIBTEX","volume":"10","author":"A Oba","year":"2020","unstructured":"Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD, Del Chiaro M. Neoadjuvant treatment in pancreatic cancer. Front Oncol. 2020;10:245. https:\/\/doi.org\/10.3389\/FONC.2020.00245\/BIBTEX.","journal-title":"Front Oncol."},{"issue":"4","key":"15281_CR63","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/SLA.0000000000002600","volume":"269","author":"T Michelakos","year":"2019","unstructured":"Michelakos T, Pergolini I, del Castillo CF, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Surg. 2019;269(4):733\u201340. https:\/\/doi.org\/10.1097\/SLA.0000000000002600.","journal-title":"Ann Surg."},{"key":"15281_CR64","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejca.2021.10.023","volume":"160","author":"JL van Dam","year":"2022","unstructured":"van Dam JL, Janssen QP, Besselink MG, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. Eur J Cancer. 2022;160:140\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2021.10.023.","journal-title":"Eur J Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15281-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15281-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15281-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T16:16:40Z","timestamp":1718036200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15281-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["15281"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15281-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"26 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This study was exempt from full ethical approval, as no original data was included.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"While a review protocol was not prepared, our study was prospectively registered with PROSPERO (CRD42022346060).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Protocol"}},{"value":"This study was accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior Presentation Information"}}]}}